EUVIMEDEUVIMED entdecken
Crossref

GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk

Tong Xu, Bin Lu, Feifeng Song, Bo Jiang, Shaobo Gong, Yuxiang Ma, Yiwen Zhang, Ping Huang, Minghua Ge

Cancer Letters · 2026-09 · 656 · 218650

DOI: 10.1016/j.canlet.2026.218650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Tong Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Thrombospondin 1, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Myeloid Cells. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province, Key Research and Development Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aggressive and immunotherapy-resistant characteristics of anaplastic thyroid carcinoma (ATC) are driven by an immunosuppressive tumor microenvironment and intercellular crosstalk; however, its regulatory mechanisms remain poorly understood. Here, we identified Glucose-6-Phosphate Isomerase (GPI) as a pivotal metabolic immune checkpoint that orchestrates myeloid cells-driven immunosuppression in ATC. We demonstrated that GPI enhances the hexosamine biosynthesis pathway to promote O-GlcNAcylation of thrombospondin-1 (THBS1) at serine-1068. This site-specific modification competes with ubiquitination to stabilize THBS1 and augment its secretion. Released THBS1 engages macrophages to trigger a CEBPB-dependent transcriptional program that drives the expression of the chemokine CCL2. Macrophage-derived CCL2 then acts on tumor-associated neutrophils, promoting their STAT3-dependent differentiation into polymorphonuclear myeloid-derived suppressor cells, which ultimately suppresses CD8+ T cell function. Genetic deletion of either GPI or THBS1 robustly inhibited tumor growth and reversed immunosuppression in vivo. To intervene this axis, we repurposed the multi-kinase inhibitor Regorafenib as a novel GPI inhibitor. We confirmed that Regorafenib disrupts this entire axis and, in combination with anti-PD-1 therapy in ATC, overcomes immunosuppression to elicit potent anti-tumor immunity. Our studies revealed the GPI/O-GlcNAcylation/THBS1 signal as a master regulator of myeloid cell crosstalk and established a novel therapeutic strategy for targeting this metabolic checkpoint to potentiate ATC immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombospondin 1Thyroid Carcinoma, AnaplasticThyroid NeoplasmsMyeloid CellsAnimalsHumansMiceTumor MicroenvironmentCell Line, TumorMacrophages

Stichwörter der Autor:innen

Anaplastic thyroid carcinomaGPIImmunosuppressive microenvironmentMacrophageNeutrophilO-GlcNAcylationTHBS1

Substanzen

Thrombospondin 1thrombospondin-1, humanThbs1 protein, mouse

Autor:innen und Institutionen

  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China; Zhejiang Provincial Clinica…
  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, 310014, China; Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, 310014, China; Otolaryngology & Head and…

Förderung

  • Medical Science and Technology Project of Zhejiang Province
  • Natural Science Foundation of Zhejiang Province
  • Key Research and Development Program of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Xu, T., Lu, B., Song, F., Jiang, B., Gong, S., Ma, Y., Zhang, Y., Huang, P., & Ge, M. (2026). GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk. Cancer Letters, 656, 218650. https://doi.org/10.1016/j.canlet.2026.218650

Vancouver

Xu T, Lu B, Song F, Jiang B, Gong S, Ma Y, et al. GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk. Cancer Letters. 2026;656:218650. doi:10.1016/j.canlet.2026.218650

BibTeX
@article{Xu2026,
  author = {Xu, Tong and Lu, Bin and Song, Feifeng and Jiang, Bo and Gong, Shaobo and Ma, Yuxiang and Zhang, Yiwen and Huang, Ping and Ge, Minghua},
  title = {GPI promotes immunosuppression in anaplastic thyroid carcinoma via O-GlcNAcylated THBS1-mediated myeloid cell crosstalk},
  journal = {Cancer Letters},
  year = {2026},
  volume = {656},
  pages = {218650},
  doi = {10.1016/j.canlet.2026.218650}
}
Kostenlos starten →